Cancer Immunotherapies Market Worth $75.8 Billion By 2022

Global Cancer Immunotherapies Market to 2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years.

Cancer is a group of diseases characterized by abnormal cell growth. It is a multi-step process, as a single mutation is almost certainly insufficient to cause a cell to become malignant. A number of cellular processes must be deregulated to allow cells to proliferate uncontrollably while evading apoptosis. Initially, key cell growth, proliferative and pro-apoptotic signaling pathways are deregulated in most cancers. These signaling pathways enable cell survival, continued proliferation, and the avoidance of programmed cell death.

It is now widely believed that many tumors express antigens that can be identified by the adaptive immune system, and that can therefore potentially be used to produce an anti-tumor immune response. The immune system is believed to have the greatest potential in terms of treating cancer, as there is evidence tumors are recognized by the immune system, and this tumor-specific immune response is due to the recognition of tumor antigens. However, in many cancers, disease progression is also accompanied by immune suppression, which hinders an effective anti-tumor response and tumor elimination.

Complete Report Available at: .

Over the past few decades cancer immunotherapies have developed into important therapeutic options for some types of cancer. Some of these therapies generally enhance the activity of the body’s immune system, while others drive the immune system to target specific cancer cells.

The different types of cancer immunotherapies used to treat cancer include monoclonal antibodies (mAbs) directed at specific tumor-associated antigens (TAA); immune checkpoint inhibitors, which target key proteins involved in the immune response, such as programmed cell death-1 (PD-1); cancer vaccines, which can be used to stimulate an immune response in a patient; and non-specific immunotherapies, which are therapies that do not target cancer cells specifically, but stimulate the immune system in a more general way, such as interferon therapy.

Overall, there are 2,037 products in active development in the cancer immunotherapy pipeline. This makes it a notable portion of the entire oncology pipeline, and reflects the strong interest in this class of therapy in product development. This is due to growing clinical rationale behind developing such therapies, and the willingness of drug developers to invest in novel therapeutics, which will offer significant product differentiation from market competitors.

The leading indications in terms of cancer immunotherapy product development are breast cancer, melanoma, non-small-cell lung cancer (NSCLC) and ovarian cancer, which are the focus of this report. This is based on the high level of activity in terms of cancer immunotherapy product development in these specific oncology indications, with the aforementioned indications ranking highest in this regard.

Get Sample of the Report at: .

Report Scope

The cancer immunotherapies market already consists of some commercially successful products.
- Which classes of drug dominate the market?
- What additional benefits have newly approved therapies brought to the market?
The cancer immunotherapies pipeline is vast, with a significant degree of diversity in terms of molecule types and targets.
- Which molecular targets appear most frequently in the pipeline?
- What are the commercial prospects for the most promising late-stage pipeline products?
The cancer immunotherapies market is forecast to rise from a value of $16.9 billion in 2015 to $75.8 billion in 2022, at a compound annual growth rate of 23.9%.

Inquire about Report at: .

Table of Contents
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 11
3 Key Marketed Products 42
4 Pipeline Landscape Assessment 58
5 Multi-scenario Market Forecast to 2022 88
6 Company Analysis and Positioning 109
7 Strategic Consolidations 114
8 Appendix 126
8.1 Bibliography 126
8.2 All Pipeline Drugs by Phase of Development 136
8.2.1 Discovery 136
8.2.2 Preclinical 160
8.2.3 IND/CTA-filed 242
8.2.4 Phase I 245
8.2.5 Phase II 284
8.2.6 Phase III 346
8.2.7 Pre-registration 355
8.2.8 Unknown 357
8.3 Abbreviations 358
8.4 Disease List 360
8.5 Methodology 360
8.5.1 Coverage 361
8.5.2 Secondary Research 361
8.5.3 Market Size and Revenue Forecasts 361
8.5.4 Pipeline Analysis 362
8.5.5 Competitive Landscape 362
8.6 Contact Us 362
8.7 Disclaimer 363

Purchase this Report at: .

Contact Info:
Name: Sameer Joshi
Email: Send Email
Organization: ReportsWeb
Address: Pune, India.
Phone: +1-646-491-9876

Release ID: 160502